ESTRELLA IMMUNOPHARMA, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 13.41 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-13
- ESTRELLA IMMUNOPHARMA, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 13.78M shares.
- ESTRELLA IMMUNOPHARMA, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-09-30 was 2.21M shares, a 0.00% decline year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-09-30 was 2.21M shares.
- ESTRELLA IMMUNOPHARMA, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 29.11M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | 13.41M shares 10-Q · filed 2026-08-13 | |||||
| 2026-03-31 | 13.78M shares 10-Q · filed 2026-05-18 | |||||
| 2025-12-31 | 5.81M shares 10-K · filed 2026-03-18 | 5.81M shares 10-Q · filed 2026-08-13 | ||||
| 2025-09-30 | 2.21M shares 10-Q · filed 2025-11-12 | |||||
| 2025-06-30 | 2.21M shares 10-Q · filed 2025-08-12 | |||||
| 2024-12-31 | 5.81M shares 10-K · filed 2026-03-18 | 2.21M shares 10-Q · filed 2025-08-12 | ||||
| 2024-09-30 | 2.21M shares 10-Q · filed 2024-11-14 | |||||
| 2024-06-30 | 2.21M shares 10-Q · filed 2024-11-14 | |||||
| 2024-03-31 | 2.21M shares 10-Q · filed 2024-05-15 | |||||
| 2023-12-31 | 2.21M shares 10-Q · filed 2024-02-14 | |||||
| 2023-09-30 | 2.21M shares 10-Q · filed 2023-11-20 | |||||
| 2023-06-30 | 29.11M shares 10-K · filed 2024-09-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |